PURPOSE: Src is overexpressed or hyperactivated in a variety of human cancers, including thyroid carcinoma. Src is a central mediator in multiple signaling pathways that are important in oncogenesis and cancer progression. In this study, we evaluated the effects of an Src inhibitor, SKI-606 (bosutinib), in a spontaneous metastatic thyroid cancer model with constitutively activated Src (Thrb(PV/PV)Pten(+/-) mice). EXPERIMENTAL DESIGN: Thrb(PV/PV)Pten(+/-) mice were treated with SKI-606 or vehicle controls, beginning at 6 weeks of age until the mice succumbed to thyroid cancer. We assessed the effects of SKI-606 on thyroid cancer progression and analyzed the impact of SKI-606 on aberrant Src-mediated signaling. RESULTS: SKI-606 effectively inhibited aberrant activation of Src and its downstream targets to markedly inhibit the growth of thyroid tumor, thereby prolonging the survival of treated mice. While Src inhibition did not induce cell apoptosis, it decreased cell proliferation by affecting the expression of key regulators of cell-cycle progression. Importantly, SKI-606 dramatically prevented dedifferentiation, vascular invasion, and lung metastasis of thyroid cancer cells. These responses were meditated by downregulation of mitogen-activated protein kinase pathways and inhibition of the epithelial-mesenchymal transition. CONCLUSIONS: Our findings suggest that Src is critical in the progression of thyroid cancer, making oral SKI-606 a promising treatment strategy for refractory thyroid cancer.
PURPOSE:Src is overexpressed or hyperactivated in a variety of human cancers, including thyroid carcinoma. Src is a central mediator in multiple signaling pathways that are important in oncogenesis and cancer progression. In this study, we evaluated the effects of an Src inhibitor, SKI-606 (bosutinib), in a spontaneous metastatic thyroid cancer model with constitutively activated Src (Thrb(PV/PV)Pten(+/-) mice). EXPERIMENTAL DESIGN:Thrb(PV/PV)Pten(+/-) mice were treated with SKI-606 or vehicle controls, beginning at 6 weeks of age until the mice succumbed to thyroid cancer. We assessed the effects of SKI-606 on thyroid cancer progression and analyzed the impact of SKI-606 on aberrant Src-mediated signaling. RESULTS:SKI-606 effectively inhibited aberrant activation of Src and its downstream targets to markedly inhibit the growth of thyroid tumor, thereby prolonging the survival of treated mice. While Src inhibition did not induce cell apoptosis, it decreased cell proliferation by affecting the expression of key regulators of cell-cycle progression. Importantly, SKI-606 dramatically prevented dedifferentiation, vascular invasion, and lung metastasis of thyroid cancer cells. These responses were meditated by downregulation of mitogen-activated protein kinase pathways and inhibition of the epithelial-mesenchymal transition. CONCLUSIONS: Our findings suggest that Src is critical in the progression of thyroid cancer, making oral SKI-606 a promising treatment strategy for refractory thyroid cancer.
Authors: Caroline S Kim; Vasily V Vasko; Yasuhito Kato; Michael Kruhlak; Motoyasu Saji; Sheue-Yann Cheng; Matthew D Ringel Journal: Endocrinology Date: 2005-07-07 Impact factor: 4.736
Authors: Jennifer M Golas; Judy Lucas; Carlo Etienne; Jonathan Golas; Carolyn Discafani; Latha Sridharan; Erwin Boghaert; Kim Arndt; Fei Ye; Diane H Boschelli; Fangbiao Li; Craig Titsch; Christine Huselton; Inder Chaudhary; Frank Boschelli Journal: Cancer Res Date: 2005-06-15 Impact factor: 12.701
Authors: Hiroko Furumoto; Hao Ying; G V R Chandramouli; Li Zhao; Robert L Walker; Paul S Meltzer; Mark C Willingham; Sheue-Yann Cheng Journal: Mol Cell Biol Date: 2005-01 Impact factor: 4.272
Authors: G F Scheumman; C Hoang-Vu; Y Cetin; O Gimm; J Behrends; R von Wasielewski; A Georgii; W Birchmeier; A von Zur Mühlen; H Dralle Journal: J Clin Endocrinol Metab Date: 1995-07 Impact factor: 5.958
Authors: Datsun A Hsia; Satyajit K Mitra; Christof R Hauck; Daniel N Streblow; Jay A Nelson; Dusko Ilic; Shuang Huang; Erguang Li; Glen R Nemerow; Jay Leng; Kathryn S R Spencer; David A Cheresh; David D Schlaepfer Journal: J Cell Biol Date: 2003-03-03 Impact factor: 10.539
Authors: Sang Jin Kim; Jin Woo Park; Ji Sung Yoon; Ji O Mok; Yeo Joo Kim; Hyeong Kyu Park; Chul Hee Kim; Dong Won Byun; Yong Jin Lee; So Young Jin; Kyo Il Suh; Myung Hi Yoo Journal: J Korean Med Sci Date: 2004-10 Impact factor: 2.153
Authors: Neil Beeharry; Eugenia Banina; James Hittle; Natalia Skobeleva; Vladimir Khazak; Sean Deacon; Mark Andrake; Brian L Egleston; Jeffrey R Peterson; Igor Astsaturov; Timothy J Yen Journal: Cell Cycle Date: 2014-06-23 Impact factor: 4.534
Authors: Woo Kyung Lee; Won Gu Kim; Laura Fozzatti; Sunmi Park; Li Zhao; Mark C Willingham; David Lonard; Bert W O'Malley; Sheue-Yann Cheng Journal: Endocr Relat Cancer Date: 2020-04 Impact factor: 5.678
Authors: Ying C Henderson; Rafael Toro-Serra; Yunyun Chen; Junsun Ryu; Mitchell J Frederick; Ge Zhou; Gary E Gallick; Stephen Y Lai; Gary L Clayman Journal: Head Neck Date: 2013-06-01 Impact factor: 3.147